893566-75-1

Basic information

• Product Name: TERT-BUTYL 8-BROMO-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE
• Synonyms: TERT-BUTYL 8-BROMO-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE;2-BOC-8-BROMO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE;N-BOC-1,2,3,4-tetrahydro-8-broMo-isoquinoline
• CAS NO: 893566-75-1
• Molecular Formula: C₁₄H₁₈BrNO₂
• Molecular Weight: 312.20222
• Mol File: 893566-75-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 382.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.353±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.60±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 8-BROMO-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 8-BROMO-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE(893566-75-1)
• EPA Substance Registry System: TERT-BUTYL 8-BROMO-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE(893566-75-1)

Safety Data

• Hazardous Substances Data: 893566-75-1(Hazardous Substances Data)

Usage

Uses

tert-Butyl 8-Bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate is an Amide compound; having BET proteolysis-inducing action, and medicinal application thereof.

Upstream product

• 226942-29-6 6-bromo-1,2,3,4-tetrahydroisoquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75416-51-2 8-bromo-1,2,3,4-tetrahydroisoquinoline 
• 63927-22-0 8-bromo-isoquinoline 

Downstream Products

• 893566-72-8 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 893566-73-9 tert-butyl 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1423161-80-1 tert-butyl 8-(6-(N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)sulfamoyl)-1-methyl-1H-indol-3-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Relevant articles and documents

COMPOUNDS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds;and intermediates useful in the preparation of the compounds.

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS

This disclosure relates, inter alia, to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.

Certain pyrazoline derivatives with kinase inhibitory activity

The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.